METHYLTHIONINIUM FOR TREATING SYNAPTOPATHIES Russian patent published in 2025 - IPC A61K31/5415 A61P25/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method for therapeutic treatment of a disorder representing synaptopathy in a mammal subject by increasing the level of synaptophysin in the brain of a subject, where the disorder is selected from a list consisting of: schizophrenia; cerebral ischemia; multiple sclerosis; depression; startle syndrome; Tourette's syndrome; autism spectrum disorders; focal dystonia of hands; experimental allergic encephalitis; glaucoma; lysosomal storage disease not associated with tau pathology, wherein the method comprises oral administration of methylthioninium (MT)-containing compound to said individual, where the MT-containing compound is a LMTX compound of the following formula:

, where H_nA and H_nB in each case are protic acids, which may be identical or may differ, and where p=1 or 2; q=0 or 1; n=1 or 2; (p + q) × n = 2, where the total daily dose is from 2 to 100 mg MT, and to a method for the preventive treatment of a disorder representing a synaptopathy in a subject, where the disorder is selected from a list consisting of: schizophrenia; cerebral ischemia; multiple sclerosis; depression; startle syndrome; Tourette's syndrome; autism spectrum disorders; focal dystonia of hands; experimental allergic encephalitis; glaucoma; lysosomal storage disease not associated with tau pathology, where the method comprises the oral administration to said individual of a methylthioninium (MT)-containing compound, where the MT-containing compound is an LMTX compound of the following formula:

, where H_nA and H_nB in each case are protic acids, which may be the same or may differ, and where p=1 or 2; q=0 or 1; n=1 or 2; (p + q) × n = 2, where the subject is a person who is assessed as predisposed to or having a risk of the disorder, where the total daily dose ranges from 2 to 100 mg MT.

EFFECT: present invention provides an increase in the level of synaptophysin in different areas of the brain in therapeutically significant doses.

18 cl, 4 dwg, 3 tbl, 4 ex